2.INFLUENCE OF DIETARY ENERGY RESTRICTION ON THE GROWTH, DEVELOPMENT AND ENDURANCE IN CHINESE KUNMING MICE
Xiufa SUN ; Jiyao WANG ; Qian YING ; Wangsheng YANG ; Jianru ZHENG
Acta Nutrimenta Sinica 1956;0(02):-
0.2); whereas that in group Ⅲ 1.24 ?0.38g, significantly different (P0.05),the dietary energy re-striction did not affect the producing and scavenging of free radical in theorgans.
3.Study on the difference of A-scan and IOL Master in measuring intraocular lens power
Qian, ZHANG ; Yue, HUANG ; Jing-Ying, YE ; Yan, ZHENG
International Eye Science 2016;16(10):1924-1926
AIM: To compare the difference of A-scan and lOL Master in intraocular lens power measurement.
●METHODS:Two hundred and twenty-six patients (230 eyes) with age-related cataract were included in the study. Before surgery, axial length was measured by A-scan and lOL Master respectively and corneal curvature was measured by auto refractometer. lntraocular lens power was calculated according to the SRK-T formula. Corneal curvature was measured by auto refractometer and the refractive outcome was performed by phoropter three months after cataract surgery.
●RESULTS:The mean axial length was (23. 48 ± 1. 94) mm measured by A-scan and (23. 75±1. 96) mm measured by lOL Master. There was significant difference between them ( P < 0. 05 ). After random grouping, the preoperative and postoperative mean corneal curvature in A-scan group was (43. 94±1. 81) D and (43. 98±1. 87) D respectively. There was no statistically significant difference between them (P>0. 05). And the results were (44. 10 ± 1. 57 ) D and ( 44. 11 ± 1. 58 ) D in lOL Master group. There was no significant difference between them (P>0. 05); The mean absolute refractive error (MAE) in A-scan group was ( 0. 47 ± 0. 27 ) D and in lOL Master group (0. 41±0. 19) D. The difference was significant (P<0. 05).
●CONCLUSION: lOL Master is proved to be slightly more accurate than A-scan for lOL power calculation.
4.Trend in incidence of stroke in Jindong District from 2016 to 2022
ZHENG Ying ; CHEN Shu ; QIAN Yanmei ; TANG Xiaocui ; LI Xiuyang
Journal of Preventive Medicine 2023;35(7):611-614
Objective:
To investigate the trends in incidence of stroke in Jindong District, Jinhua City, Zhejiang Province from 2016 to 2022, so as to provide to the evidence for improving the stroke control strategy.
Methods:
The incidence of stroke in Jindong District from 2016 to 2022 was collected through the Zhejiang Chronic Disease Monitoring Information System, and standardized by the data of the Chinese National Population Census in 2010. The gender-, age- and subtype-specific incidence of stroke was calculated, and the trends in stroke incidence were investigated with average annual percent change (AAPC).
Results:
A total of 9 159 stroke cases were reported in Jindong District from 2016 to 2022, with crude incidence of 386.52/105 and standardized incidence of 276.75/105. The crude incidence of stroke appeared a tendency towards a rise (AAPC=3.704%, 95%CI: 0.792%-6.700%, P<0.05), while the standardized incidence showed no significant changing patterns (P>0.05). The crude incidence of stroke was significantly higher among men than among women (438.69/105 vs. 334.66/105; χ2=14.028, P<0.05), and the standardized incidence of stroke was significantly higher among men than among women (316.58/105 vs. 237.31/105; χ2=6.985, P<0.05). The crude incidence of stroke appeared a tendency towards a rise with age(χ2=5 290.180, P<0.05), and the crude incidence of stroke appeared a tendency towards a decline with age among residents at ages of 45 to 64 years (AAPC=-9.135%, 95%CI: -15.003% to -2.861%, P<0.05), while no significant changing patterns were found in the crude incidence of stroke among residents at other age groups (P>0.05). The crude incidence of ischemic stroke was significantly higher than that of hemorrhagic stroke (306.08/105 vs. 76.89/105; χ2=137.184, P<0.05).
Conclusions
The incidence of stroke appeared a tendency towards a rise in Jindong District from 2016 to 2022, with ischemic stroke as the predominant subtype. Male and middle-aged and elderly populations should be given a high priority for stroke control.
5.Sperm acrosome formation-associated genes in mice: Advances in studies.
Chang-min NIU ; Jia-qian GUO ; Hai-tao MA ; Zhe ZHENG ; Ying ZHENG
National Journal of Andrology 2016;22(1):72-76
Spermiogenesis is a complex process of differentiation and morphologic alteration, in which sperm acrosome formation is an important stage. Acrosome is an essential component of the sperm head, which develops in four distinct phases: Golgi, cap, acro- somal, and maturation, each supported by precise and orderly regulation of various genes. The regulatory genes which act on Golgi ap- paratus include GOPC, Hrb, SPATA16, PICK1, and CK2α', those involved in the cap phase are Fads2, syntaxin 2, Kdm3a, and UBR7, and participating in acrosomal and maturation phases are KIFC1, Rnf19a, and DPY19L2. The abnormalities of these genes may affect male fertility by influencing the connection of the nuclear dense lamina and acroplaxome with the nuclear membrane and then the fusion and transportation of vesicles. This review focuses on the genes involved in different phases of acrosome formation.
Acrosome
;
physiology
;
Animals
;
Golgi Apparatus
;
Male
;
Mice
;
Sperm Head
;
physiology
;
Spermatids
;
growth & development
;
Spermatogenesis
;
genetics
;
Spermatozoa
;
growth & development
6.Molecular Cloning and Characterization of a Glutathione S-transferase Gene Repressed by Phenylacetic Acid From Penicillium chrysogenum
Fuqiang WANG ; Guizhen ZHENG ; Ying ZHAO ; Zhihong REN ; Qian JIA ; Jiangong HE ; Jun YU
Progress in Biochemistry and Biophysics 2006;33(12):1223-1230
Glutathione S-transferase (GST) gene, PcgstA was cloned from the penicillin producing strain Penicillium chrysogenum,which is important for understanding the industrial fermentation process. PcgstA gene has an open-reading-frame of 840 bp in length,which is interrupted by two introns. The deduced amino acid sequence shows about 50% identity to several characterized filamentous fungi GSTs. The recombinant PcGSTA in Escherichia coli were overexpressed and purified. Enzymatic assays showed that the recombinant PcGSTA had a specific activity with 1-chloro-2, 4-dinitrobenzene of (0.159±0.031) μmol/(min· mg). It was found that the expression level of PcgstA in the penicillin producing medium supplemented with phenylacetic acid, the side chain precursor of penicillin G, was significant down regulated than that in medium without phenylacetic acid. This result suggested that PcGST may be related to phenylacetic acid metabolism in the penicillin producing strain.
7.Lifitegrast: A novel inhibitor of integrin for dry eye disease
Fei ZHENG ; Yanmei WANG ; Qian ZHANG ; Ying GONG ; Yuanyuan GU ; Guodong HUA
Drug Evaluation Research 2017;40(6):880-884
Lifitegrast is a novel inhibitor of integrin,which can take effect by blocking the binding of intercellular adhesion molecule 1 and integrin lymphocyte function associated antigen 1.In July 2016,the U.S.Food and Drug Administration (FDA) officially approved the application of lifitegrast ophthalmic solution 5% (commodity name XiidraTM).Clinical trials of the drug include a 12-week phase II clinical trial and three 12-week phase III clinical trials for dry eye disease patients.The results of clinical trials have demonstrated the efficacy and safety of the drug.Lifitegrast is the first FDA approved drug to improve and treat dry eye symptoms,and other similar drug is only cyclosporine.It is believed that in the near future clinical application of lifitegrast will be more extensive.
8.Etelcalcetide: A new drug for secondary hyperparathyroidism of chronic kidney disease
Fei ZHENG ; Yanli ZHANG ; Qian ZHANG ; Ying GONG ; Yuanyuan GU ; Guodong HUA
Drug Evaluation Research 2017;40(3):428-432
Etelcalcetide (ParsabivTM) is a second generation calcimimetic agent newly developed by Amgen,mainly used for the treatment of secondary hyperparathyroidism.Etetcalcetide not only decreases calcium concentration by directly binding with the calcium sensing receptor,but also reduces the parathyroid hormone level.The European Union has approved for chronic kidney disease patients with secondary hyperparathyroidism in dialysis with Etelcalcetide injection.This paper summarized the pharmacological effects,pharmacokinetics,clinical trials,and adverse reaction of Etelcalcetide.
9.Meta analysis of brain metastases ideal treatment mode
Ying LI ; Xiaomeng FANG ; Da JIANG ; Qian DONG ; Zengye ZHANG ; Fei ZHENG
Journal of International Oncology 2015;42(2):103-108
Objective To explore the ideal treatment mode of brain metastases by Meta-analysis.Methods Articles were searched for from the databases at home and abroad using English and Chinese keywords.Searching time limited from the databases setting up to December 30,2012.Jadad score was applied to evaluate the qualities of literatures.RevMan5.0 software was applied to perform the Meta-analysis.A totle of 25 articles including 2 750 patients were eligible for the Meta-analysis,which divided into groups with different treatment.Results Compared with monotherapy,combined therapy improved 1-year survival (OR =0.58,95% CI:0.46 ~0.71,P <0.000 01).In combined therapy groups,compared with two methods,three kinds of therapies improved 1-year survival (OR =0.63,95 % CI:0.50 ~ 0.80,P =0.000 1).Compared with local therapy only or systemic therapy only,systemic combined local therapy improved 1-year survival (OR =0.68,95% CI:0.53 ~ 0.86,P =0.001 ; OR =0.59,95% CI:0.41 ~ 0.86,P =0.006).In systemic combined local therapy groups,three kinds of treatments improved 1-year survival compared with two methods (OR =0.52,95% CI:0.35 ~ 0.78,P =0.002).Compared with non-molecular targeted therapy,molecular targeted therapy improved 1-year survival (OR =0.76,95% CI:0.67 ~ 0.87,P < 0.000 1).Conclusion The reasonable treatment for patients with brain metastases is combined treatment with operation,radiotherapy and chemotherapy.There is better curative effect added molecular targeted therapy based on original scheme,if patients have targeted therapy indications.
10.Characterization and phylogenetic analysis of chloroplast genome of Cynanchum wallichii and Cynanchum otophyllum
Ying-min GENG ; Xing-qian ZHOU ; Ti-cao ZHANG ; Lan-ping ZHENG
Acta Pharmaceutica Sinica 2024;59(3):764-774
italic>Cynanchum wallichii and